Aclaris Therapeutics to Participate in 2026 Cantor Global Healthcare Conference
News provided byAclaris Therapeutics, Inc · 1 min read
WAYNE, Pa., Sept. 03, 2026 /CourierPR/ -- Aclaris Therapeutics, a clinical-stage biopharmaceutical company based in the United States, will participate in the 2026 Cantor Global Healthcare Conference. The conference, set to take place in New York on Thursday, September 10, 2026, at 2:45 PM Eastern Time, will feature Aclaris' Chief Executive Officer, Dr. Neal Walker, in a fireside chat.
The event is open to attendees and will also be live-streamed online, with the webcast available on Aclaris' website for at least 30 days following the conference. Interested parties can access the webcast through the company's Events page at www.aclaristx.com.
Dr. Walker, a key figure in the company's leadership, will share insights into Aclaris' innovative product candidates and progress in developing treatments for patients with immuno-inflammatory diseases. Aclaris focuses on developing novel therapies to address unmet medical needs, with a robust research and development pipeline.
According to the company's website, Aclaris Therapeutics is dedicated to advancing treatments for patients suffering from conditions such as psoriasis, atopic dermatitis, and other inflammatory diseases. The firm's portfolio includes several clinical-stage product candidates, each designed to provide better outcomes for patients who currently lack effective treatment options.
For those unable to attend the live event, the webcast will serve as a valuable resource, providing detailed information on Aclaris' latest developments and future plans. The event is expected to attract a wide range of healthcare professionals, investors, and industry experts.
Aclaris Therapeutics' participation in the Cantor Global Healthcare Conference underscores the company's commitment to innovation and its role in advancing medical research and treatment options. The webcast will be available on the company's website for at least 30 days, allowing viewers to revisit the discussion at their convenience.